| Followers | 39 |
| Posts | 2870 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2003 |
Friday, August 03, 2018 5:40:17 AM
With quarterly revenue declining in Q2 5% from a year ago, this is now an unmitigated disaster. These new approved drugs should be generating 80% revenue growth year over year from these small bases. The Docs aren’t promoting PETX’s compounds..
Strange, BR, I have a very different angle on it with my rose-colored glasses on.
As you must know I concentrate on Galliprant because of the huge relief for our dog, who was a goner without the drug.
Aratana recorded $1.9 million in licensing and collaboration revenue in the second quarter of 2018 for GALLIPRANT(R) (grapiprant tablets), which was generated from Elanco Animal Health (a division of Eli Lilly & Co.) recording approximately $10 million in net product sales. According to third-party market research conducted in June 2018, GALLIPRANT, which is for the control of pain and inflammation associated with osteoarthritis in dogs, continues to grow market share in a competitive category and is the second-leading NSAID prescribed by veterinarians. Assuming GALLIPRANT quarterly sales trends remain consistent, Aratana expects to achieve a $15.0 million commercial milestone in 2018.
Pisses me off they call Galliprant an NSAID. It is the only drug, steroid or NSAID, I can find for the worn out condition of osteoarthritis that does not shut off the flow of lubricants to the joints but instead increases them. My wife would love to be young again with such a drug. Anyway it's a life-saver.
Hopefully the sarcoma drug will be another big winner whenever the rubes at the Agriculture Department approve it. I think it's when, not if, from published results and talks outside of PETX.
Unlike the cancer drug, it seems PETX could have a HUGE winner with worldwide human development of Galliprant drug.
Am I just blowing smoke? Gave up smoking years ago.
We have much more riding on the EP4 receptor antagonist than filthy lucre. My wife has an appointment finally with a rheumatologist Monday to get a better diagnosis. My little sister has osteo and rheumotoid arthritis alongside severe osteoporosis that killed our mother and older half-sister but she is now planning a return trip to Africa. I have to help my wife dress.
Maybe I can be forgiven my enthusiasm for Galliprant.
All the best to you and yours.
Best, Terry
Strange, BR, I have a very different angle on it with my rose-colored glasses on.
As you must know I concentrate on Galliprant because of the huge relief for our dog, who was a goner without the drug.
Aratana recorded $1.9 million in licensing and collaboration revenue in the second quarter of 2018 for GALLIPRANT(R) (grapiprant tablets), which was generated from Elanco Animal Health (a division of Eli Lilly & Co.) recording approximately $10 million in net product sales. According to third-party market research conducted in June 2018, GALLIPRANT, which is for the control of pain and inflammation associated with osteoarthritis in dogs, continues to grow market share in a competitive category and is the second-leading NSAID prescribed by veterinarians. Assuming GALLIPRANT quarterly sales trends remain consistent, Aratana expects to achieve a $15.0 million commercial milestone in 2018.
Pisses me off they call Galliprant an NSAID. It is the only drug, steroid or NSAID, I can find for the worn out condition of osteoarthritis that does not shut off the flow of lubricants to the joints but instead increases them. My wife would love to be young again with such a drug. Anyway it's a life-saver.
Hopefully the sarcoma drug will be another big winner whenever the rubes at the Agriculture Department approve it. I think it's when, not if, from published results and talks outside of PETX.
Unlike the cancer drug, it seems PETX could have a HUGE winner with worldwide human development of Galliprant drug.
Am I just blowing smoke? Gave up smoking years ago.
We have much more riding on the EP4 receptor antagonist than filthy lucre. My wife has an appointment finally with a rheumatologist Monday to get a better diagnosis. My little sister has osteo and rheumotoid arthritis alongside severe osteoporosis that killed our mother and older half-sister but she is now planning a return trip to Africa. I have to help my wife dress.
Maybe I can be forgiven my enthusiasm for Galliprant.
All the best to you and yours.
Best, Terry
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
